One post from Danielle Marie Gray's dossier. This page reviews a single piece of material. The full dossier cross-checks 9 materials and carries the verified credential and scope verdicts.
Read the full dossier →/api/archive/snapshots/1c1aade756dc7b1f49af94cce97cf140e67904cdaa5c14f13de88a269f90a6bb/page.html
View dossier →Danielle Marie Gray alias The Upper-Neck Checkout
moving supplement units at Restore Health & Longevity Center
Facebook · 100055718364406
Practice location
250 W LANCASTER AVE
WAYNE, PA 19087
Mostly evidence, with a few persuasion patterns mixed in.
- Of 16 health claims, 5 run counter to or conflict with the published evidence, and 7 were not independently checked.
- Primary persuasion tactic: Nervous-system halo.
- Stated credentials look inflated relative to the advice given.
- Gives advice beyond what their license covers.
Gray has mastered the ancient funnel art of turning every commute, workout, and phone glance into a reason to book the upper-cervical appointment. The nervous system gets a cameo, the landing page gets the starring role, and the checkout link waits patiently in the bio.
Moderate signals
Score breakdown
Direct answer
Danielle Marie Gray is licensed in Pennsylvania as a chiropractor (DC), not as an MD or DO, and Pennsylvania's chiropractic scope statute (63 P.S. § 625.102) limits that license to musculoskeletal care, not the diagnosis or treatment of systemic disease. Even so, they advertise diagnosing or treating Hyperactivity (ADHD), Chronic Fatigue, Depression, Diabetes, and Fibromyalgia, conditions that belong with appropriately board-certified physicians.
Key findings
- False Authority: The description invokes the nervous system to make a specialized chiropractic intervention sound broadly restorative, without specifying a validated mechanism or measurable clinical benefit beyond symptom-focused care.see section ↓
- Claim "Upper cervical care helps the body function and recover more efficiently by addressing up…": not supported by peer-reviewed evidence.see section ↓
- Claim "Small, repetitive daily activities can cause repetitive stress in the upper neck that aff…": only partially supported.see section ↓
- NPI registry confirms danielle marie gray as Chiropractor (DC) in Pennsylvania (NPI 1093019549).see section ↓
- Danielle Marie Gray shows credential inflation relative to stated vs likely credentials.see section ↓
- Dr Danielle Marie Gray is marketed with a doctor title, but reviewed credentials indicate Chiropractor (DC) rather than an MD/DO physician license.see section ↓
- Against Pennsylvania State Board of Chiropractic scope rules (63 P.S. § 625.102), these advertised activities appear outside Danielle Marie Gray's license (including conditions they merely list as ones they treat): Hyperactivity (ADHD), Chronic Fatigue, Depression.see section ↓
- 12 of 14 advertised activities fall outside permitted Chiropractor scope in PA.see section ↓
Claims & evidence
12 advertised conditions or treatments fall outside their license scope. Each box leads with state-board scope notation; literature cross-check follows when we matched a specific claim. Every card carries its receipts: the quoted wording, a live source link, and an archived copy.
Danielle Marie Gray is not licensed or approved by Pennsylvania State Board of Chiropractic to diagnose, treat, or cure Hyperactivity (ADHD).
Hyperactivity (ADHD)
- Supports
- Licensed treatments for ADHD, including stimulant medications such as methylphenidate and amphetamines and nonstimulants such as atomoxetine and guanfacine, reduce core ADHD symptoms in randomized trials and meta-analyses, particularly in the short term. [1][3] A large network meta-analysis supports methylphenidate as a preferred first-choice medication in children and adolescents and amphetamines in adults when efficacy and safety are considered. [2][4][5] Clinical guidance recommends FDA-approved medication and/or evidence-based behavioral therapy, tailored to age, symptoms, impairment, comorbidities, and adverse effects.
- Contradicts
- The index list does not establish that any unspecified treatment is licensed or effective for ADHD: only the Lancet review is directly relevant, while the other listed records concern unrelated conditions or interventions. [1][2][3] The claim is too fragmentary to identify a particular licensed product, treatment, patient group, or outcome. ADHD treatments generally manage symptoms and functional impairment; the evidence does not show that they cure or permanently eliminate ADHD. [5] Benefits, risks, and regulatory approval differ by jurisdiction and medication.
- Mainstream view
- ADHD is treated with an individualized, multimodal plan that may include licensed medication and behavioral or psychosocial interventions. Stimulants are commonly first-line pharmacological treatments, with nonstimulants used in selected situations; treatment requires diagnosis, monitoring, dose adjustment, and periodic review. [2][3][5] The phrase licensed treatment of Hyperactivity (ADHD) is not itself a complete, assessable medical claim because it does not specify the intervention or therapeutic outcome. [1]
“Hyperactivity (ADHD)”
Rule: 63 P.S. § 625.102
Danielle Marie Gray is not licensed or approved by Pennsylvania State Board of Chiropractic to diagnose, treat, or cure Chronic Fatigue.
Chronic Fatigue
- Supports
- Licensed clinicians can provide individualized symptom management for chronic fatigue or ME/CFS, including treatment of sleep problems, pain, orthostatic intolerance, and comorbid conditions. [15][16][17] Some prescription medicines may be used for associated symptoms, but this is not the same as a licensed treatment for chronic fatigue itself. The listed index papers concern B-cell malignancies, respiratory papillomatosis, primary biliary cholangitis, EBV, bronchiectasis, and immune thrombocytopenia, and do not support treatment of chronic fatigue . [6][7][8][9][10][11][12][13][14]
- Contradicts
- For ME/CFS specifically, the CDC states that there is no cure or FDA-approved treatment, and that care focuses on symptom relief and self-management rather than a disease-modifying licensed treatment. [12][13][14][15][16][17] Major guidance recommends individualized activity management or pacing and symptom-directed care; NICE advises against fixed-increment graded exercise therapy and limits cognitive behavioral therapy to supportive use. Therefore, the claim provides no identifiable treatment, indication, or outcome and is not supported by the cited papers or established guidance.
- Mainstream view
- There is no universally licensed or approved treatment that cures or specifically treats chronic fatigue syndrome/ME/CFS. [16][17] Clinicians evaluate alternative causes of fatigue and manage confirmed comorbidities and symptoms individually, while avoiding interventions that worsen post-exertional malaise. [15] The phrase licensed treatment of Chronic fatigue is too vague to identify a specific intervention or medically testable outcome. [13]
“Chronic Fatigue”
Rule: 63 P.S. § 625.102
See every doc bro advertising Chronic fatigue and fibromyalgia
Danielle Marie Gray is not licensed or approved by Pennsylvania State Board of Chiropractic to diagnose, treat, or cure Depression.
Depression
- Supports
- Depression has multiple licensed, evidence-based treatments, including antidepressant medication and psychotherapy recommended in clinical practice guidelines. [27][28] Internet-based cognitive behavioral therapy has evidence of efficacy for depression. [19] Augmentation strategies, ketamine or electroconvulsive therapy, and other interventions may benefit selected patients, particularly those with treatment-resistant depression. [18][20][22][25] Esketamine nasal spray is an approved treatment option for treatment-resistant depression, with studies reporting maintained response during longer-term treatment. [21][23][26][29]
- Contradicts
- The phrase "licensed treatment of Depression" is not a complete or specific clinical claim: it does not identify a particular treatment, jurisdiction, depression subtype, patient group, or outcome. [20][21][22][23][25][27] The listed studies support specific interventions, not an unspecified treatment. Psilocybin, deep-brain stimulation, and some forms of transcranial electrical stimulation remain investigational or have limited evidence and should not be assumed to be licensed treatments based on these papers. [18][24][28]
- Mainstream view
- Depression is a treatable medical disorder, but treatment should be selected after clinical assessment according to severity, diagnostic features, patient preferences, comorbidities, safety considerations, and prior response. [18][20][21][22][23][25] Established options include evidence-based psychotherapy and licensed antidepressant medications; electroconvulsive therapy and specialized treatments such as esketamine are reserved for appropriate indications. [19][28] A generic statement that there is a licensed treatment for depression is broadly true, but it is too vague to establish the safety, effectiveness, or licensing of any particular influencer-promoted intervention. [27]
“Depression”
Rule: 63 P.S. § 625.102
Danielle Marie Gray is not licensed or approved by Pennsylvania State Board of Chiropractic to diagnose, treat, or cure Diabetes.
Diabetes
- Supports
- Licensed treatments are available for diabetes, including lifestyle interventions and approved medicines such as metformin, sulfonylureas, SGLT2 inhibitors, GLP-1 receptor agonists, and insulin, selected according to diabetes type, complications, and individual circumstances. [30][31][32] WHO guidance identifies metformin as a usual initial treatment for type 2 diabetes, with other medicines and insulin used when indicated. [34] The index results also include a systematic review showing that intensive glucose control can reduce some nonfatal myocardial infarctions and microvascular outcomes in type 2 diabetes, although this does not establish a single licensed treatment or diabetes cure. [33]
- Contradicts
- The phrase licensed treatment of Diabetes is too vague to support a specific therapeutic claim: it does not identify the diabetes type, treatment, jurisdiction, indication, or outcome. [31][32] The listed index papers do not directly establish a general licensed treatment claim; one is about clinical-trial reporting for artificial intelligence, several are unrelated clinical-trial records, and the diabetes meta-analysis concerns intensive glycaemic control rather than licensing. [30][33][34] Intensive control does not reliably reduce all-cause or cardiovascular mortality and increases severe hypoglycaemia risk.
- Mainstream view
- Diabetes is managed with evidence-based, regulator-approved treatments and lifestyle measures, but treatment must be individualized by diabetes type and clinical context. [31][32][33][34] Approved treatment is not synonymous with cure or reversal, and claims about licensing require a named intervention and relevant regulatory jurisdiction. The claim as stated is therefore too nonspecific to verify as a substantive medical claim.
“Diabetes”
Rule: 63 P.S. § 625.102
Danielle Marie Gray is not licensed or approved by Pennsylvania State Board of Chiropractic to diagnose, treat, or cure Fibromyalgia.
Fibromyalgia
- Supports
- The claim is a general topic rather than a specific intervention or outcome, but reliable guidance supports providing people with fibromyalgia emotional support, practical help with daily tasks, education, and connection with healthcare professionals and support resources. [35] The 2025 patient guideline specifically identifies family and friends as sources of emotional support and help with daily activities. Evidence also supports helping the person engage, according to their abilities and preferences, with individualized education, exercise, psychological therapies, and multidisciplinary care; systematic reviews find benefits for pain, function, quality of life, sleep, or mood, although certainty varies. [36][37][38]
- Contradicts
- None of the supplied index records directly evaluates how a loved one should support someone with fibromyalgia; they are unrelated clinical-trial registrations. [35][38] Evidence for specific caregiver behaviors, communication techniques, or caregiver-led treatment effects is therefore not established by the index list. Support should not be coercive or assume that exercise, activity, or any single treatment is appropriate for everyone, because fibromyalgia symptoms and responses are heterogeneous and much nonpharmacological evidence is low or moderate certainty.
- Mainstream view
- Supporting a loved one with fibromyalgia generally means believing and validating their symptoms, listening to their preferences, helping with practical tasks when requested, encouraging appropriate medical care and self-management without pressure, and adapting activity to fluctuating symptoms. [35][37][38] Education, individualized exercise or rehabilitation, psychological approaches, sleep management, and multidisciplinary care may help, but family support complements rather than replaces professional assessment and treatment. Because the claim is only a heading and gives no specific advice, its factual accuracy cannot be judged as a particular recommendation.
“Fibromyalgia”
Rule: 63 P.S. § 625.102
See every doc bro advertising Chronic fatigue and fibromyalgia
Danielle Marie Gray is not licensed or approved by Pennsylvania State Board of Chiropractic to diagnose, treat, or cure High Blood Pressure.
High Blood Pressure
- Supports
- Evidence-based treatment for diagnosed high blood pressure is supported by major guidelines. The WHO recommends pharmacological treatment for adults with confirmed hypertension, generally starting at blood pressure of at least 140/90 mmHg, and recommends thiazide or thiazide-like diuretics, ACE inhibitors or ARBs, and long-acting dihydropyridine calcium-channel blockers as initial options. [39][41][42] The WHO guideline also supports treatment initiation and blood-pressure targets based on cardiovascular disease, diabetes, chronic kidney disease, and overall risk. [40]
- Contradicts
- The supplied index papers do not provide direct evidence for treating high blood pressure: they concern glycemic monitoring, rheumatoid arthritis exercise, angioplasty, medical education, heart failure devices, mHealth for noncommunicable diseases, training, and neck-pain therapy. [39][41] In particular, the listed studies are not hypertension treatment trials, so none directly supports the claim. [42] The phrase licensed treatment is too nonspecific to establish which intervention, indication, regulatory jurisdiction, or outcome is being claimed.
- Mainstream view
- High blood pressure should be confirmed with appropriate blood-pressure measurement and managed with lifestyle measures and, when indicated, licensed antihypertensive medicines prescribed and monitored by qualified clinicians. [39] Common first-line drug classes include thiazide-type diuretics, ACE inhibitors or ARBs, and calcium-channel blockers. Treatment is individualized according to blood pressure level, cardiovascular risk, age, comorbidities, tolerance, and pregnancy status. The generic label does not identify a specific treatment, and the supplied index papers are irrelevant to evaluating it. [41][42]
“High Blood Pressure”
Rule: 63 P.S. § 625.102
Danielle Marie Gray is not licensed or approved by Pennsylvania State Board of Chiropractic to diagnose, treat, or cure Irritable Bowel Syndrome (IBS).
Irritable Bowel Syndrome (IBS)
- Supports
- There are licensed and guideline-recommended treatments for specific IBS symptom patterns, including linaclotide and other guanylate cyclase activators or chloride-channel activators for IBS with constipation, and rifaximin for IBS with diarrhea. [46] The ACG guideline recommends these therapies for symptom improvement, not cure. [43][45] The listed microbiota-and-diet paper supports IBS as involving complex diet–microbiota associations, but it does not establish a licensed treatment for IBS. [44]
- Contradicts
- The claim is too fragmentary to identify a specific treatment, indication, jurisdiction, or outcome, and none of the listed index papers demonstrates that a particular intervention is licensed to treat IBS. [44] The STRICTA paper concerns reporting acupuncture trials rather than treatment licensing or efficacy. [43] The remaining listed records concern unrelated conditions and do not support IBS treatment. Current guidance describes management as symptom control using diet, lifestyle measures, psychological therapies, and selected medications; it does not identify a treatment that cures IBS. [45][46]
- Mainstream view
- IBS has several licensed or routinely prescribed treatments for particular subtypes and symptoms, but no universally licensed treatment that eliminates the underlying disorder or reliably cures IBS. [43][44][46] Treatment is individualized and aims to reduce abdominal pain, constipation, diarrhea, and overall symptom burden.
“Irritable Bowel Syndrome (IBS)”
Rule: 63 P.S. § 625.102
Danielle Marie Gray is not licensed or approved by Pennsylvania State Board of Chiropractic to diagnose, treat, or cure Dysautonomia.
Dysautonomia
- Supports
- Dysautonomia is a broad category of autonomic nervous-system disorders with condition-specific treatments, including nonpharmacologic measures and medications for particular symptoms or subtypes. For POTS, structured exercise, increased fluids and salt, compression garments, and selected off-label medications may improve symptoms; the 2015 expert consensus supports several of these options with limited-to-moderate evidence . [51][53] The listed index papers on COVID-19 outcomes and long-COVID symptoms provide context for autonomic symptoms after COVID-19 but do not establish a licensed dysautonomia treatment . [49][50][52]
- Contradicts
- The claim is too nonspecific to identify what treatment, disorder subtype, licensing jurisdiction, or outcome is meant. [52] Current reviews and clinical guidance state that no FDA-approved medication is specifically indicated for POTS, a common form of dysautonomia, and that no single therapy has been proven successful for all patients. [50][51] Medications such as propranolol, midodrine, fludrocortisone, pyridostigmine, and ivabradine are generally used off-label for POTS, while treatments licensed for related conditions are not thereby licensed to treat dysautonomia as a whole. [53] The supplied index results mostly concern unrelated trials and do not support the claim .
- Mainstream view
- Dysautonomia is not one disease and does not have one universally licensed treatment. [52] Management depends on the specific diagnosis and cause, beginning commonly with education, hydration and salt strategies, physical reconditioning, compression, and treatment of underlying disease; medications or specialist interventions may be added for selected symptoms. [50][53][54] Claims that a generic treatment is licensed for dysautonomia require a named intervention and regulatory jurisdiction, and are not supported as stated.
“Dysautonomia”
Rule: 63 P.S. § 625.102
See every doc bro advertising MCAS and histamine intolerance
Danielle Marie Gray is not licensed or approved by Pennsylvania State Board of Chiropractic to diagnose, treat, or cure Epilepsy & Seizure Disorders.
Epilepsy & Seizure Disorders
No specific health claims of theirs were cross-checked against the literature.
“Epilepsy & Seizure Disorders”
Rule: 63 P.S. § 625.102
Danielle Marie Gray is not licensed or approved by Pennsylvania State Board of Chiropractic to diagnose, treat, or cure Multiple Sclerosis.
Multiple Sclerosis
- Supports
- Multiple licensed disease-modifying treatments exist for multiple sclerosis, particularly for relapsing forms, and ocrelizumab is licensed for selected early primary progressive disease; major guidelines recommend treatment selection, monitoring, switching, and stopping strategies. [55][57][58][59][60][61][62][63][64][65] The cited systematic review found that several disease-modifying therapies reduce relapses, MRI disease activity, or progression in relapsing-remitting MS, and that ocrelizumab probably reduces progression in primary progressive MS. The cited molecular and therapeutic review describes established pharmacological interventions for MS.
- Contradicts
- The phrase is not a complete claim about a specific treatment, indication, country, or outcome. The cited papers on optic neuritis, encephalitis, MRI diagnosis, and McDonald diagnostic criteria do not establish licensing or efficacy of a particular MS treatment. [55][56][57][58][60] The paper on repurposing licensed Epstein-Barr-virus-active drugs presents a systematic approach and does not show that those drugs are licensed treatments for MS. [62][63][64] One listed paper concerns SOD1 ALS rather than MS and is irrelevant to this claim. [61]
- Mainstream view
- Multiple sclerosis has numerous licensed disease-modifying therapies, but licensing is indication- and jurisdiction-specific, and these treatments generally reduce relapses, new MRI lesions, and/or disability progression rather than cure MS. [57][58][59][62][63][64][65] Treatment should be individualized by MS subtype, disease activity, risks, comorbidities, and patient preferences. [55][61] As written, the fragment does not identify what treatment is being claimed, so it cannot be validated as a specific influencer claim.
“Multiple Sclerosis”
Rule: 63 P.S. § 625.102
Danielle Marie Gray is not licensed or approved by Pennsylvania State Board of Chiropractic to diagnose, treat, or cure Seizure Disorders.
Seizure Disorders
- Supports
- Licensed antiseizure medications are established treatments for many epilepsies, selected according to seizure type and epilepsy syndrome. [68][73][74][75][78] The Cochrane network meta-analysis evaluated antiseizure-drug monotherapy for epilepsy . [70][76] SANAD II provides randomized evidence for medication selection in newly diagnosed focal epilepsy . [71] Fenfluramine reduced seizures associated with Lennox-Gastaut syndrome in a randomized clinical trial . [69] International consensus guidance supports diagnosis- and syndrome-specific management of Dravet syndrome . [67][72][77]
- Contradicts
- The phrase does not identify a specific treatment, indication, or meaning of “licensed treatment. [76][77] ” Seizure disorders include epileptic seizures and functional seizures, which require different management; antiseizure medication is not an appropriate treatment for functional neurological disorder when epilepsy is absent . [67][68][69][70][71][72][74][75][78] Licensed therapies generally reduce seizure frequency or treat emergencies rather than universally curing or eliminating seizure disorders. Evidence and regulatory indications vary by seizure type, age, syndrome, country, and treatment resistance .
- Mainstream view
- There are multiple licensed, evidence-based treatments for epileptic seizure disorders, including antiseizure medications and, for selected patients, dietary, surgical, device-based, or syndrome-specific therapies. [72][73][74][75][78] Treatment requires confirmed diagnosis and specialist selection because not every seizure-like event is epilepsy and no single licensed treatment applies to all seizure disorders. [67][68] Therefore, the label is broadly compatible with mainstream medicine only if it means that licensed treatments exist for some seizure disorders; it is too nonspecific to establish a particular treatment claim. [69][71][76][77]
“Seizure Disorders”
Rule: 63 P.S. § 625.102
Danielle Marie Gray is not licensed or approved by Pennsylvania State Board of Chiropractic to diagnose, treat, or cure How to Support a Loved One with Fibromyalgia.
How to Support a Loved One with Fibromyalgia
- Supports
- The claim is a general topic rather than a specific intervention or outcome, but reliable guidance supports providing people with fibromyalgia emotional support, practical help with daily tasks, education, and connection with healthcare professionals and support resources. [35] The 2025 patient guideline specifically identifies family and friends as sources of emotional support and help with daily activities. Evidence also supports helping the person engage, according to their abilities and preferences, with individualized education, exercise, psychological therapies, and multidisciplinary care; systematic reviews find benefits for pain, function, quality of life, sleep, or mood, although certainty varies. [36][37][38]
- Contradicts
- None of the supplied index records directly evaluates how a loved one should support someone with fibromyalgia; they are unrelated clinical-trial registrations. [35][38] Evidence for specific caregiver behaviors, communication techniques, or caregiver-led treatment effects is therefore not established by the index list. Support should not be coercive or assume that exercise, activity, or any single treatment is appropriate for everyone, because fibromyalgia symptoms and responses are heterogeneous and much nonpharmacological evidence is low or moderate certainty.
- Mainstream view
- Supporting a loved one with fibromyalgia generally means believing and validating their symptoms, listening to their preferences, helping with practical tasks when requested, encouraging appropriate medical care and self-management without pressure, and adapting activity to fluctuating symptoms. [35][37][38] Education, individualized exercise or rehabilitation, psychological approaches, sleep management, and multidisciplinary care may help, but family support complements rather than replaces professional assessment and treatment. Because the claim is only a heading and gives no specific advice, its factual accuracy cannot be judged as a particular recommendation.
“How to Support a Loved One with Fibromyalgia”
Rule: 63 P.S. §625.101 et seq. (Chiropractic Practice Act)
See every doc bro advertising Chronic fatigue and fibromyalgia
Manipulation
transcript · cited
The description invokes the nervous system to make a specialized chiropractic intervention sound broadly restorative, without specifying a validated mechanism or measurable clinical benefit beyond symptom-focused care. Likely motive: Increase perceived medical authority and convert viewers with neck discomfort into consultation leads.
“Upper cervical care focuses on the alignment of the upper spine and its relationship with the nervous system”
transcript · cited
The post turns a general neck-pain message into a direct consultation call to action. No product or lab upsell is shown, but the consultation itself is the monetized next step. Likely motive: Generate cash-pay or practice-service consultations from people who identify with common neck symptoms.
“Schedule your initial consultation with Dr. Gray. Click the link in our bio for scheduling.”
Commerce & grift map
The visible funnel is symptom-focused content leading directly to an initial consultation, not a supplement-plus-lab sequence. The copy does not establish referral fees, dispensing markups, affiliate commissions, or proprietary products.
No FTC-style compensation disclosure
compensationDisclosures · scan
Host self-funnel around guest content
guestCollaboration · selfFunnel
Host booking/consult links: https://fb.uppercervicalcare.com/57vf9e7f
Credentials & scope
Glossary: Chiropractor (“Dr.”)
Learn: Is a chiropractor a medical doctor?
Stated: none · Likely: Chiropractor
Verified against the federal provider registry: D.C. · Chiropractor · PA license DC010324.
The clip supplies no degree, license, specialty, or board information for Gray. The title appears in the booking call to action, but the underlying credential cannot be verified from this content surface.
- Chiropractor (DC), Doctor of Chiropractic
Chiropractic scope is generally limited to evaluation and treatment of musculoskeletal and nervous-system conditions through spinal adjustment and authorized adjunctive therapies, not general internal medicine, prescription pharmacology, or primary disease management.
Permitted scope vs advertised
Pennsylvania State Board of Chiropractic · Confidence: high
Pennsylvania defines chiropractic as addressing relationships involving the vertebral column, other articulations, and the neuro-musculoskeletal system, including examination, adjustment or manipulation, necessary patient care, limited diagnosis needed to determine the nature and appropriateness of chiropractic treatment, specified adjunctive procedures, and nutritional counseling. The practice excludes drugs, surgery, obstetrics and gynecology, fracture reduction, and major dislocations; adjunctive procedures require Board certification.
What this license permits
- Spinal adjustment and manipulation
- Musculoskeletal evaluation and treatment
- Soft-tissue and rehabilitative care
- Headache care within musculoskeletal scope
12 of 14 advertised activities fall outside permitted scope.
| Advertised | Verdict |
|---|---|
| Listed service Hyperactivity (ADHD) Rule: 63 P.S. § 625.102 Diagnosing ADHD as a standalone neurodevelopmental disorder is not affirmatively authorized because Pennsylvania permits diagnosis only when necessary to determine the nature and appropriateness of chiropractic treatment. | Outside scope |
| Listed service Chronic Fatigue Rule: 63 P.S. § 625.102 Diagnosing chronic fatigue as a systemic condition is not affirmatively authorized beyond diagnosis necessary to select chiropractic treatment for the vertebral, articular, or related nervous-system conditions covered by the Act. | Outside scope |
| Listed service Depression Rule: 63 P.S. § 625.102 Diagnosing depression as a mental-health disorder is outside the Act’s affirmative authorization for diagnosis limited to determining appropriate chiropractic treatment. | Outside scope |
| Listed service Diabetes Rule: 63 P.S. § 625.102 Diagnosing or managing diabetes as a systemic metabolic disease is not affirmatively authorized by Pennsylvania’s chiropractic scope provision. | Outside scope |
| Listed service Fibromyalgia Rule: 63 P.S. § 625.102 Diagnosing fibromyalgia as a systemic pain disorder is not affirmatively authorized except to the limited extent a diagnosis is necessary to determine appropriate chiropractic treatment for covered musculoskeletal or related nervous-system conditions. | Outside scope |
| Listed service High Blood Pressure Rule: 63 P.S. § 625.102 Diagnosing or treating hypertension as a systemic cardiovascular condition is not affirmatively authorized by the Pennsylvania Chiropractic Practice Act. | Outside scope |
| Listed service Irritable Bowel Syndrome (IBS) Rule: 63 P.S. § 625.102 Diagnosing IBS as a gastrointestinal disorder is not affirmatively authorized by the chiropractic scope definition or its limited diagnosis provision. | Outside scope |
| Listed service Dysautonomia Rule: 63 P.S. § 625.102 Diagnosing dysautonomia as a systemic autonomic-nervous-system disorder is not affirmatively authorized apart from diagnosis necessary to select chiropractic treatment for a covered related nervous-system condition. | Outside scope |
| Listed service Epilepsy & Seizure Disorders Rule: 63 P.S. § 625.102 Diagnosing epilepsy or seizure disorders as neurologic diseases is not affirmatively authorized by Pennsylvania’s limited chiropractic diagnosis provision. | Outside scope |
| Listed service Multiple Sclerosis Rule: 63 P.S. § 625.102 Diagnosing or managing multiple sclerosis as a systemic neurologic disease is not affirmatively authorized by the chiropractic scope definition. | Outside scope |
| Listed service Seizure Disorders Rule: 63 P.S. § 625.102 Diagnosing seizure disorders as neurologic diseases is not affirmatively authorized by Pennsylvania’s chiropractic diagnosis provision. | Outside scope |
| Listed service How to Support a Loved One with Fibromyalgia Rule: 63 P.S. §625.101 et seq. (Chiropractic Practice Act) | Outside scope |
Sources: Chiropractic Practice Act, Act 188 of 1986 (official), Pennsylvania State Board of Chiropractic official page (official), 49 Pa. Code § 5.81, Unprofessional and immoral conduct (official), 49 Pa. Code § 5.6. Fees. (official)
Tip the jar
Report useful? Optional tips help keep scans, archives, and literature cross-checks running. They never change conclusions.
Submission nS0nlQKrSxnJNYAdpGZ2Y
Fight disinformation
Log a public thread where Danielle Marie Gray is spreading nonsense, get a copy-paste reply with this report link.
Reply snippets
Before you buy the protocol: Dr. Trust Me Bro fact-checked Danielle Marie Gray's claims with peer-reviewed sources, https://drtrustmebro.com/analyze/nS0nlQKrSxnJNYAdpGZ2Y. White-coat charisma isn't evidence.
Full DTMB scan on Danielle Marie Gray: https://drtrustmebro.com/analyze/nS0nlQKrSxnJNYAdpGZ2Y
Drop these in YouTube comments, Reddit threads, and forums, link back to this scan, not vibes.
Recent mentions (this doc)
No conversation links logged yet. Be the first above.
Nudge the Doc Bro
We email a public contact address from their site so Danielle Marie Gray can review this dossier and dispute anything we got wrong.
Know someone who can help?
If you think someone has firsthand information about Danielle Marie Gray, send them an encouraging note. We email a short, respectful message with this report and clear instructions on how to write in, on the record or anonymously.
Whambulance
Challenge this scan or Wall of Fame entry for Danielle Marie Gray. Public log, not legal arbitration.
Public challenge log
No posted Wall of Fame challenges linked yet.
Challenges are public on the Wall of Fame card. DTMB does not remove entries for hurt feelings, primary sources or copy corrections only.
File a challenge
Include in your email:
- Doc Bro ID: 1U-WPfozpk446qhbe6XuJ
- Wall entry: /influencer/1U-WPfozpk446qhbe6XuJ
- Analysis ID: nS0nlQKrSxnJNYAdpGZ2Y
- Source: https://www.facebook.com/reel/1041519731606550/
- Why this entry or scan should change
- Supporting links (one per line)
- Your business email (for verified disputes)
Verified challenges are posted publicly on the report. Public log, not legal arbitration.
Citations
Peer-reviewed and index sources cited in this report.
- [1] Attention deficit hyperactivity disorder
- [2] Systematic Review and Meta-Analysis: Effects of Pharmacological ...
- [3] Relationship Between Treatment Duration and Efficacy of Pharmacological Treatment for ADHD: A Meta-Analysis and Meta-Regression of 87 Randomized Controlled Clinical Trials - PubMed
- [4] meta-analysis of 63 studies enrolling 11788 patients - PubMed
- [5] Comparative efficacy and acceptability of pharmacological, psychological ...
- [6] Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
- [7] PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial.
- [8] Primary biliary cholangitis.
- [9] New Treatment Paradigms in Primary Biliary Cholangitis.
- [10] Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors.
- [11] Neutrophilic inflammation in bronchiectasis.
- [12] Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study.
- [13] Evaluating rilzabrutinib in the treatment of immune thrombocytopenia.
- [14] What Primary Care Practitioners Need to Know about the New NICE ...
- [15] Managing Specific Symptoms of ME/CFS: Orthostatic Intolerance, Sleep Problems, Pain, and Memory/Concentration Problems
- [16] ME/CFS Clinical Care for Severely Affected Patients
- [17] Manage ME/CFS
- [18] Transcranial Electrical Stimulation in Treatment of Depression: A Systematic Review and Meta-Analysis.
- [19] Internet-Based Cognitive Behavioral Therapy for Depression: A Systematic Review and Individual Patient Data Network Meta-analysis.
- [20] Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial.
- [21] Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.
- [22] Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis.
- [23] Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study.
- [24] Technology of deep brain stimulation: current status and future directions.
- [25] Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial.
- [26] Depressive disorders: systematic review of approved ... - PMC
- [27] Summary of the clinical practice guideline for the treatment ...
- [28] New and emerging pharmacologic treatments for MDD - PMC
- [29] Depressive disorders: systematic review of approved ...
- [30] Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension
- [31] [PDF] Diagnosis and Management of Type 2 Diabetes - IRIS
- [32] Diagnosis and Management of Type 2 Diabetes - IRIS
- [33] A systematic review and meta-analysis of trials ...
- [34] Intensive glycaemic control for patients with type 2 diabetes
- [35] 285 Non-pharmacological interventions for people with fibromyalgia: a systematic review
- [36] Systematic review of randomized controlled trials of ...
- [37] FRI0702-HPR NON PHARMACOLOGICAL MANAGEMENT OF FIBROMYALGIA: A SYSTEMATIC REVIEW OF SYSTEMATIC REVIEWS
- [38] A SYSTEMATIC REVIEW WITH BAYESIAN NETWORK ...
- [39] Preventing and treating...
- [40] More people die each year from cardiovascular disease (CVD) than from any other cause.
- [41] Guideline for the pharmacological treatment of ...
- [42] Guideline for the pharmacological treatment of hypertension ...
- [43] Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): Extending the CONSORT Statement
- [44] Intestinal Microbiota And Diet in IBS: Causes, Consequences, or Epiphenomena?
- [45] ACG Clinical Guideline: Management of Irritable Bowel ...
- [46] Irritable bowel syndrome in adults: diagnosis and management
- [47] Irritable bowel syndrome in adults
- [48] Irritable bowel syndrome in adults overview
- [49] Sixty-Day Outcomes Among Patients Hospitalized With COVID-19
- [50] Symptoms and risk factors for long COVID in non-hospitalized adults
- [51] Postural orthostatic tachycardia syndrome (POTS): State of ... - PMC
- [52] Systematic literature review: treatment of postural orthostatic ... - PMC
- [53] The evidence for treatments for postural orthostatic ...
- [54] Management of Postural Orthostatic Tachycardia Syndrome ... - PMC
- [55] Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment.
- [56] Encephalitis.
- [57] 2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis.
- [58] Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria.
- [59] Multiple sclerosis: molecular pathogenesis and therapeutic intervention.
- [60] Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management.
- [61] Tofersen treatment leads to sustained stabilization of disease in SOD1 ALS in a "real-world" setting.
- [62] Repurposing Licensed Drugs with Activity Against Epstein-Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach.
- [63] Table 1, FDA-approved disease-modifying treatments for MS
- [64] Disease-modifying therapies for adults with multiple ...
- [65] Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis
- [66] Table 1.
- [67] Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders.
- [68] Epilepsy with myoclonic-atonic seizures: an update on genetic causes, nosological limits, and treatment strategies.
- [69] Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome: A Randomized Clinical Trial.
- [70] Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
- [71] The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
- [72] International consensus on diagnosis and management of Dravet syndrome.
- [73] Defining Dravet syndrome: An essential pre-requisite for precision medicine trials.
- [74] Epidemiology of Developmental and Epileptic Encephalopathy and of Intellectual Disability and Epilepsy in Children.
- [75] Update on Antiseizure Medications 2025
- [76] Clinical practice guidelines for the administration of third ...
- [77] A5 CONSENSUS GUIDELINES ON THE MANAGEMENT OF EPILEPSY_240729 ...
- [78] Epilepsies in children, young people and adults - NCBI - NIH